• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Opthea Limited

    7/3/24 7:15:39 PM ET
    $OPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $OPT alert in real time by email
    SC 13G/A 1 z72243sc13ga4.htm AMENDMENT NO. 4

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 4)*

     

    Opthea Limited
    (Name of Issuer)
    Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value
    (Title of Class of Securities)
     
    68386J208
    (CUSIP Number)
     
    June 28, 2024
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    o Rule 13d-1(c)

     

    o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
       
     

     

    SCHEDULE 13G

     

      CUSIP No. 68386J208    
    1 Names of Reporting Persons

    Regal Funds Management Pty Limited
    2 Check the appropriate box if a member of a Group (see instructions)

    (a)  o
    (b)  o
    3 SEC Use Only

     

     

    4 Citizenship or Place of Organization

    Sydney, Australia

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5 Sole Voting Power

     
    6 Shared Voting Power

     

    312,995,827 (1)

    7 Sole Dispositive Power

     
    8 Shared Dispositive Power

     

    312,995,827 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    312,995,827(1)
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    o
    11 Percent of class represented by amount in row (9)


    28.68%

    12 Type of Reporting Person (See Instructions)

    FI
                 

    ___________________________

    1 The number of shares beneficially owned includes: (i) 289,736,603 Ordinary Shares, no par value (“Ordinary Shares”) and (ii) 2,907,403 American Depositary Shares, each representing eight Ordinary Shares.

     

     Page 2 of 6 
     

     

    SCHEDULE 13G

     

      CUSIP No. 68386J208    
    1 Names of Reporting Persons

    Regal Partners Limited
    2 Check the appropriate box if a member of a Group (see instructions)

    (a)  o
    (b)  o
    3 SEC Use Only

     

     

    4 Citizenship or Place of Organization

    Sydney, Australia

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting Person
    With:

    5 Sole Voting Power

     
    6 Shared Voting Power

     

    312,995,827 (2)

    7 Sole Dispositive Power

     
    8 Shared Dispositive Power

     

    312,995,827 (1)

    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    312,995,827(1)
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    o
    11 Percent of class represented by amount in row (9)


    28.68%

    12 Type of Reporting Person (See Instructions)

    FI
                 

    ___________________________

    2 The number of shares beneficially owned includes: (i) 28,736,603 Ordinary Shares, no par value (“Ordinary Shares”) and (ii) 2,907,403 American Depositary Shares, each representing eight Ordinary Shares.

     

     Page 3 of 6 
     

     

    Item 1.

     

    (a)Name of Issuer: Opthea Limited

     

    (b)Address of Issuer’s Principal Executive Offices: Level 4, 650 Chapel Street, South Yarra, Victoria 3141, Australia

     

    Item 2.

     

    (a) Name of Person Filing: Regal Funds Management Pty Limited and Regal Partners Limited

     

    (b)Address of Principal Business Office or, if None, Residence: Level 47, Gateway, 1 Macquarie Place, Sydney NSW 2000

     

    (c)Citizenship:       Australian

     

    (d)Title and Class of Securities: Ordinary Shares, no par value and American Depositary Shares, each representing eight Ordinary Shares, no par value

     

    (e)CUSIP No.:       68386J208

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)o     Broker or dealer registered under Section 15 of the Act;

     

    (b)o     Bank as defined in Section 3(a)(6) of the Act;

     

    (c)o     Insurance company as defined in Section 3(a)(19) of the Act;

     

    (d)o     Investment company registered under Section 8 of the Investment Company Act of 1940;

     

    (e)o     An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    (f)o     An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

    (g) x     A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

     

    (h)o     A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)o     A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

     

    (j)x     A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);

     

    (k)o     Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    Item 4. Ownership

     

    (a)Amount Beneficially Owned:       312,995,827

     

     Page 4 of 6 
     

     

    (b)Percent of Class: 28.68%

     

    (c)Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote:

     

    (ii)Shared power to vote or to direct the vote: 312,995,827

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    (iv)Shared power to dispose or to direct the disposition of: 312,995,827

     

    Pursuant to Rule 13d-3(a)(2), Regal Funds Management Pty Limited (“Regal”) and Regal Partners Limited (by virtue of Regal Partners Limited being the 100% owner and controller of Regal Funds Management Pty Limited) are deemed to be the beneficial owners of 312,995,827 Ordinary Shares or 28.68% of the total 1,091,466,771 Ordinary Shares reported to be outstanding as of June 20, 2024 in Opthea Limited’s Appendix 2A filed with the Australian Securities Exchange on June 20, 2024, as a result of Regal being the trustee and/or manager and/or advisor of various investment trusts.

     

    The number of shares beneficially owned includes: (i) 289,736,603 Ordinary Shares and (ii) 2,907,403 American Depositary Shares, which each represent eight Ordinary Shares.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person. Not applicable

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. Not applicable

     

    Item 8.Identification and classification of members of the group. Not applicable

     

    Item 9.Notice of Dissolution of Group. Not applicable

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief:

     

    (i) the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11; and

     

    (ii) the foreign regulatory scheme applicable to investment advisers with an Australian Financial Services Licence is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s).

     

    I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

     Page 5 of 6 
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:  3rd July 2024

     

    /s/ Kenny Ho

     

    Kenny Ho, Company Secretary, Regal Funds Management Pty Limited

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

     

     

    Page 6 of 6

     

     

    Get the next $OPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OPT

    DatePrice TargetRatingAnalyst
    3/25/2025$2.00Buy → Neutral
    H.C. Wainwright
    3/25/2025$12.00 → $1.00Outperform → Market Perform
    Leerink Partners
    3/25/2025$8.00 → $1.00Buy → Underperform
    Jefferies
    3/24/2025Outperform → Perform
    Oppenheimer
    12/8/2022$14.00Buy
    H.C. Wainwright
    4/26/2022$25.00Outperform
    SVB Leerink
    More analyst ratings

    $OPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Opthea Announces Decision to Discontinue Wet AMD Trials

      ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

      3/31/25 12:01:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Announces COAST Phase 3 Trial Topline Results

      COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

      3/24/25 12:01:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Announces Phase 2b Wet AMD Publication

      Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. The paper entitled "Sozinibercept Combination Therapy for Neovascula

      3/3/25 7:00:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Opthea Appoints Kathy Connell to Board of Directors

      Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

      11/15/24 7:00:48 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

      Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

      10/8/24 7:00:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

      MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

      7/17/24 7:15:00 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Opthea Limited

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      11/14/24 6:00:28 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Opthea Limited

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      7/3/24 7:15:39 PM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Opthea Limited (Amendment)

      SC 13G/A - Opthea Ltd (0001815620) (Subject)

      2/14/24 4:21:51 PM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Opthea Ltd. downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Opthea Ltd. from Buy to Neutral and set a new price target of $2.00

      3/25/25 8:30:12 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Ltd. downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Opthea Ltd. from Outperform to Market Perform and set a new price target of $1.00 from $12.00 previously

      3/25/25 8:25:42 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Opthea Ltd. downgraded by Jefferies with a new price target

      Jefferies downgraded Opthea Ltd. from Buy to Underperform and set a new price target of $1.00 from $8.00 previously

      3/25/25 8:25:11 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    Financials

    Live finance-specific insights

    See more
    • Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

      MELBOURNE, Australia, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Opthea Limited ((ASX:OPT, NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announce that MST Access will host an "Ask the Expert" conference call with Professor Jason S. Slakter, M.D. on Tuesday 13th December 6:30pm – 7:30pm EST USA (Wednesday 14th December 10:30am – 11:30am AEDT). Prof Slakter is a board certified Retinal and Macular Disease Specialist, Clinical Professor of Ophthalmology at New York University School of Medicine, and partner of Vitreous Retina Macula Consultants of New York. Prof Slakter will present an overview of Opthea'

      12/12/22 10:08:46 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $OPT
    SEC Filings

    See more
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      4/10/25 6:05:23 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      3/31/25 6:07:14 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Opthea Limited

      6-K - Opthea Ltd (0001815620) (Filer)

      3/24/25 6:06:42 AM ET
      $OPT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care